Surprising turns in the ongoing patent disagreement between the Broad Institute and the University of California plus two co-petitioners over much-vaunted gene editing tool, CRISPR. The Broad has asked for 13 of the four patents it currently owns to be stripped out of the larger case, meaning both parties could end up with something, rather than a winner-takes-all approach. Meanwhile, French pharmaceutical firm, Cellectis, claimed that it had been issued an umbrella patent that would cover gene-editing procedures, such as CRISPR, however, some have voiced doubt over the validity of its claim
Surprising turns in the ongoing patent disagreement between the Broad Institute and the University of California plus two co-petitioners over much-vaunted gene editing tool, CRISPR. The Broad has asked for four of the 13 patents it currently owns to be stripped out of the larger case, meaning both parties could end up with something, rather than a winner-takes-all approach. Meanwhile, French pharmaceutical firm, Cellectis, claimed that it had been issued an umbrella patent that would cover gene-editing procedures, such as CRISPR, however, some have voiced doubt over the validity of its claim